Trial Profile
A Safety Study of ARRY-502 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Oct 2020
Price :
$35
*
At a glance
- Drugs ARRY 502 (Primary)
- Indications Allergic asthma; Seasonal allergic rhinitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Array BioPharma; Pfizer
- 30 Jan 2012 Results were published in a Array BioPharma media release.
- 19 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Aug 2011 New trial record